- Home
- CURR vs BDTX Comparison
CURR vs BDTX Comparison
Compare CURR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURR | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CURR | BDTX |
|---|---|---|
| Price | $3.16 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 131.9K | ★ 545.1K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.56 | N/A |
| P/E Ratio | ★ N/A | $6.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $1.31 |
| 52 Week High | $4.68 | $4.94 |
Technical Indicators
Market Signals| Indicator | CURR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 78.71 | 64.42 |
| Support Level | $1.47 | $2.45 |
| Resistance Level | $4.68 | $2.64 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 98.39 | 94.31 |
Price Performance
Historical ComparisonAbout CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.